Gay Saunas In Gloucester

CEUTA OPHTHALMOLOGY EYE: THE VITAMIN B6, B12 and Folic Acid CAN REDUCE THE RISK OF MACULAR DEGENERATION ASSOCIATED WITH AGE IN WOMEN

A study published in the journal Archives of Internal Medicine seems to show that the daily diet supplemented with Folic Acid, Pyridoxine and Cyanocobalamin seems reduce the risk of macular degeneration associated with age in women with cardiovascular disease risk.

Epidemiological studies indicate an association between elevated levels homocysteine \u200b\u200b blood and the risk of wet AMD , so researchers Brigham and Women's Hospital, Harvard Medical School in Boston, Massachusetts, and colleagues from the Women's Antioxidant and Folic Acid Cardiovascular Study have examined results of the incidence of wet AMD in women with elevated homocysteine \u200b\u200blevels which has been treated combined with folic acid, pyridoxine (B6) and cyanocobalamin (B12) , compared with placebo. The average duration of follow up was 7.3 years.

finally The results showed a lower incidence of wet AMD in the treated group, statistically significant, reducing the risk of it.

Since there are currently no meansof prevent AMD in the initial stages, except the strict smoking ban, these results become important clinically and should be confirmed in other populations of men and women.

Arch Intern Med. 2009, 169:335-341.

Basic information and guidance. For personalized information consult your ophthalmologist.

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Laser Anniversary Joke

CEUTA OPHTHALMOLOGY EYE TREATMENT WITH LOW DOSES OF retinal vein occlusion fibrinolytic

retinapanama.com

A recent study in Retina (July / August 2009 - vol 29 - 932-940 ps) seems to indicate the improvement in outcome in patients with retinal vein occlusion treated with low doses of fibrinolytics compared to those treated with hemodilution.
x
The RESEARCHERS s ( Hattenbach, Lars-Olof MD; FRIEDRICH ARNDT, CARL MD; Lerche, RALF MD; Scharrer, INGE MD; Baatz, Holger MD, margin, FABRICE MD; Richard, Gisbert MD; BEHRENS- BAUMANN, WOLFGANG MD; OHRLOFF, CHRISTIAN MD ) Ometer s randomly 53 patients with occlusion of the central retinal vein (CRVO) or occlusion of branch retinal vein (BRVO ) to treatment with intravenous thrombolysis with 50 mg of recombinant tissue plasminogen activator (rt-PA) or hemodilution within the 11 days of onset of symptoms.
x
All patients were followed up one year.
x
Among patients with CRVO half BCVA was 20/60 in the rt-PA group compared to a BCVA of 20/400 in the hemodilution group.
x
Among patients with BRVO, there was a trend toward improved vision in rt-PA group differences did not reach statistical significance, probably due to the small number of patients group.
x
Basic information and guidance. For personalized information consult your ophthalmologist.
x

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Wedding Ribbon With Sayings

CEUTA OPHTHALMOLOGY EYE: Drops OPHTHALMIC NERVE GROWTH FACTOR IN THE TREATMENT OF GLAUCOMA OPHTHALMOLOGY

www.visionparaiso.com

A team of Italian researchers reported in the August 4 edition of Proceedings of the National Academy of Science (Act of the National Academy of Sciences), evidence shows that eye drops containing nerve growth factor improved the vision in three patients with advanced glaucoma
X
The team of researchers Alessandro Lambiase, Luigi Aloe, Marco Centofanti, Vincenzo Pariso, Flavio Mantelli, Gilberto Bucci, Stefano Bonini, Rita Levi-Montalcini and evaluated Colofrancesco Valeria effects of eye drops based on "Nerve Growth Factor" in a rat glaucoma model and subsequently developed a clinical study of three patients with progressive visual field defects despite control eye pressure.
x
Glaucoma was induced in rats by injection of hypertonic saline episcleral vein. Initially evaluated at 100 and 200 mg / mL on the results in 24 rats, determinándosa most effective dose of 200 mg / mL. A second group underwent histological, biochemical and molecular methods on a group treated for 7 weeks, bringing the best indices in relation to the control group. It was aimed at a slower loss of nerve fibers and cell death by apoptosis in the treated group versus the control group.
x
The clinical study on three patients with advanced glaucoma treated psycho and electrofuncionales parameters analyzed after three months of treatment with topical "Nerve Growth Factor."
x
treated patients showed a long-term improvement of visual field, optic nerve function, contrast sensitivity and visual acuity.
x
Studies seem to show that the factor exerts neuroprotective effects Creimiento Nervous, inhibiting apoptosis in animals with glaucoma. In the 3 patients with advanced glaucoma with topical treatment "Nerve Growth Factor" improved all parameters of visual function.
x
These results may open new therapeutic perspectives in the treatment of glaucoma and other neurodegenerative diseases of the optic nerve.
x
Integrato di Ricerca Center, Department of Ophthalmology, University of Rome "Campus Bio-Medico" and Fondazione Alberto Sordi, 00128 Rome, Italy - Institute of Neurobiology and Molecular Medicine, National Research Council, 00143 Rome, Italy - Department of Ophthalmology, University of Rome "Tor Vergata", 00133 Rome, Italy - Gian Battista Bietti Eye Foundation, Rome, Italy - European Brain Research Institute Foundation, 00143 Rome, Italy.
x
Basic information and guidance. For personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira